Ibandronic Acid Noridem Enterprises (Ibandronate Sodium Hydrate)

Ibandronate sodium hydrate binds to hydroxyapatite on bone surfaces. When osteoclasts attach to this drug‑coated bone, the compound is taken up and disrupts the mevalonate pathway, preventing prenylation of essential proteins. This triggers osteoclast apoptosis, thereby reducing bone resorption and allowing bone formation to dominate.

The dosing regimen for ibandronate sodium hydrate is determined by the prescribing clinician based on the specific indication, patient characteristics, and renal function. Common regimens include a single intravenous infusion administered once yearly for osteoporosis or a series of infusions for Paget's disease, but the exact dose and schedule must be individualized.

Safety of ibandronate sodium hydrate during pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, and it is generally avoided in pregnant or nursing women unless the potential benefit outweighs the potential risk, as determined by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Ibandronate is a potent nitrogen‑containing bisphosphonate administered intravenously, offering the convenience of once‑yearly dosing for osteoporosis, whereas agents like alendronate or risedronate are oral and require weekly or monthly dosing. Ibandronate’s rapid infusion and high affinity for bone provide effective suppression of bone turnover, but the choice of agent depends on patient preference, renal function, and clinical context.

Ibandronate sodium hydrate for injection should be stored at ambient temperature, typically below 25 °C, in its original packaging. The container should be kept protected from light and moisture. Do not freeze the solution, and avoid exposing it to extreme temperatures that could compromise stability.

Ibandronate sodium hydrate is supplied as an intravenous solution that is administered by a healthcare professional through a slow infusion into a vein. The infusion time and volume are defined by the prescribing information, and the patient is monitored for any acute reactions during and after the administration.

Serious adverse events associated with ibandronate include osteonecrosis of the jaw (ONJ), atypical femoral fractures, severe renal impairment, and symptomatic hypocalcemia. Patients should be educated to report persistent jaw pain, unusual thigh or groin pain, sudden changes in kidney function, or signs of low calcium such as muscle cramps or tingling sensations.

Ibandronate is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min), known hypersensitivity to ibandronate or any component of the formulation, and those with active dental infections or untreated dental disease that could predispose to ONJ. Caution is also advised in individuals with low calcium or vitamin D levels until these are corrected.